TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06578520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg once per day, oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg once per day, oral tablets
Study: NCT06575283

Intervention type: OTHER
Intervention: No intervention will be performed in this cohort study
Description: Deep learning classification models will be used for automatic prediction of cerebral palsy. Machines will be used to assist doctors in cerebral palsy risk evaluation.
Study: NCT06574646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAL+
Description: LAL+ IOL allows for refractive error (both sphere and cylinder) enhancements post-IOL implantation by exposing the IOL to ultraviolet (UV) light through a series of noninvasive treatments with a Light Delivery Device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clareon Vivity Toric IOL
Description: Clareon Vivity Toric IOL utilizes an extended depth of focus (EDOF) design, which incorporates nondiffractive wavefront shaping (X-WAVE) technology.
Study: NCT06497530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab will be administered intravenously at a dose of 4.5 mg/kg on Day 1 of each 21-day cycle for 4 cycles in the induction phase.~Serplulimab will be administered intravenously at a dose of 4.5 mg/kg on Day 1 of each 21-day cycle in the maintenance phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin will be administered intravenously at a fixed dose of 4 mg on Day 1 of each 21-day cycle in the maintenance phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
Study: NCT04823273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General improvement
Description: Changes to interface to be more intuitive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-line help text
Description: General improvement + in-line help text

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interruptive alert
Description: General improvement + interruptive alert
Study: NCT06496529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DoF intervention
Description: Training of specific uniarticular and single plane movement of the upper limb through an exoskeleton and videogames that will be supervised by a physiotherapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task intervention
Description: Training of multiarticular upper limb movements (vertical, horizontal and diagonal) through videogames and also training of functional task (raise and lower your hand on the table, cleaning a table, put cream on the non-paretic arm, hold a bottle, put a piece of bread or something similar in your mouth, wash your face, brush your hair, store items in a basket, brush teeth, wrote and serve water in glass). This activities will be supervised by a physiotherapist.
Study: NCT05746728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Safety run-in phase: 200-250mg, QD, Q3W~Dose expansion phase: according to the dose determined in the safety run-in phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg, d1, iv, Q3W
Study: NCT04957966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-selected relaxing music
Description: 20 minutes music listening
Study: NCT06320509

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Continuous measurement of uPO2 (both groups)
Description: uPO2 is collected continuously for the first 5 days of admission or until discharge from intensive care or removal of the urinary catheter.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Continuous measurement of uPO2 (both groups)
Description: uPO2 is collected continuously for the first 5 days of admission or until discharge from intensive care or removal of the urinary catheter.
Study: NCT05873114

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mobilization
Description: Effects of Mobilization in Management of Post-partum Backache in Females With Normal Vaginal Delivery (NVD) and Cesarean Section Delivery

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique (MET)
Description: Effects of Muscle Energy Technique (MET) in Management of Post-partum Backache in Females With Normal Vaginal Delivery (NVD) and Cesarean Section Delivery
Study: NCT06035367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive continuous monitoring device to record photoacoustic signal
Description: Neogly is in two parts, the measurement head, to be worn on the wrist and the power box, to be worn on the forearm or upper arm. The ribbon cable makes the connection between the two parts.~A handset is used to start/stop the device. The medical device record a continuous photoacoustic signal.
Study: NCT06001710

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needleless jet injector
Description: Device consist of injection pen, ampule and activator.
Study: NCT06580626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: decompression technique
Description: 14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by decompression technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guided bone regenaration using Ethoss
Description: 14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by guided bone regeneration using β-TCP/CS synthetic bone substitute.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ridge splitting technqiue
Description: 14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by ridge splitting technique using piezosurgery.
Study: NCT06341179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension
Description: Children and their parents will receive a behavioral intervention consisting of two in-person sessions and four virtual sessions. The two in-person sessions will take place at the beginning of the study (during weeks 1 and 2) and will focus on effective behavioral strategies to enhance sleep time, including goal setting (e.g., bedtimes and wake-up times), self-monitoring (via actigraphy), problem-solving and preplanning, stimulus control (i.e., sleep hygiene recommendations), and positive reinforcement. The four virtual sessions will take place at frequent intervals during the 12-week intervention (at weeks 4, 6, 8, and 10) and will act as reminders/refreshers to reinforce strategies to enhance changes in sleep time. Parents will receive advice in relation to altering only their children's sleeping routine (bedtime), and they will be instructed not to directly modify their children's food consumption or physical and sedentary activities during daytime.
Study: NCT05078190

Intervention type: OTHER
Intervention: Social Determinants of Health
Description: The study will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.

Intervention type: OTHER
Intervention: Social Determinants of Health
Description: The study will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.

Intervention type: OTHER
Intervention: Social Determinants of Health
Description: The study will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
Study: NCT04910269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
Description: The hIVIG product is administered as a single dose of 3.5 grams, or 35 milliliter at a concentration of 0.1 grams/milliliter.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of 35 milliliters standard isotonic saline
Study: NCT05735873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-energy diet
Description: Twenty-one pre-made, low-energy meals delivered weekly to the subject for 12 weeks.
Study: NCT05745077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Consultation
Description: Patients will be contacted by their surgeon over the phone to discuss surgical treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Care
Description: Patients will proceed with their surgical consultation as per standard practice.
Study: NCT04976738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cybis™ 10:25 THC:CBD oil
Description: Cybis™ 10:25 containing 10 mg/mL of D9-THC and 25 mg/mL of CBD, formulated in medium chain triglycerides (MCT)
Study: NCT06370767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bike-Share Travel Training
Description: Half of the participants not assigned to the waitlist will begin the bike-share intervention arm immediately after the baseline research interview. The bike-share arm will last for 8 weeks and be delivered by a community peer specialist. Half of the participants assigned to the waitlist will begin the bike-share intervention arm after an 8-week waiting period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Public Transportation Travel Training
Description: Half of the participants not assigned to the waitlist or bike-share arm will begin the public transportation intervention arm immediately after the baseline research interview. The public transportation arm will last for 8 weeks and be delivered by a community peer specialist. Half of the participants assigned to the waitlist will begin the public transportation intervention arm after an 8-week waiting period.
Study: NCT05579860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olezarsen
Description: Olezarsen will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olezarsen
Description: Olezarsen will be administered by SC injection.
Study: NCT04919083

Intervention type: OTHER
Intervention: Program of Therapeutic Exercise and Functional Recovery
Description: Specific hip fracture recovery programme,restoring the mobility, strength and balance of the operated patient, in order to facilitate the return to a functional state as close as possible to the state prior to surgery and in the shortest possible time, as detailed in Annex VIII. This programme is part of the standard treatment protocol implemented since January 2021 by the Orthogeriatrics Unit of the San Juan de Dios Hospital.~This programme is divided into 5 phases, each of these phases coincides with a level of the gait assessment scale. Each individual will start at the level assigned by the doctor and will only have access to the videos of the indicated level and the levels below it. As the patient meets the recovery goals, the physician will provide access to the higher level videos.The functional recovery plan begins the day after the hip fracture and continues after the patient has been discharged for a total of 16 weeks.

Intervention type: OTHER
Intervention: Standardised nursing care plan
Description: Consisting of postural changes described in the standardised nursing care plan. Within this plan, the patient was moved to a sitting position prematurely (within the first 24 hours) and started to ambulate within the following 48 hours, provided that the patient's general condition allowed it. This group did not receive any specific functional recovery plan.
Study: NCT06001710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needleless jet injector
Description: Device consist of injection pen, ampule and activator.
Study: NCT06574477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planning of alignment with HoloLens 2
Description: Planning of attachment position and traction direction with HoloLens 2 goggles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No planning of alignment with HoloLens 2
Description: No planning of attachment position and traction direction with HoloLens 2 goggles
Study: NCT06576453

Intervention type: BEHAVIORAL
Intervention: Self-questionnaire WHOQOL-bref
Description: Parents must complete the self-questionnaire WHOQOL-bref after the first and the last session of the Pepps program.
Study: NCT05124691

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Albendazole and Ivermectin fixed dose coformulation
Description: 400 mg Albendazole - 9 mg Ivermectin OR 400 mg Albendazole - 18 mg Ivermectin
Study: NCT06576453

Intervention type: BEHAVIORAL
Intervention: Self-questionnaire WHOQOL-bref
Description: Parents must complete the self-questionnaire WHOQOL-bref after the first and the last session of the Pepps program.

Intervention type: BEHAVIORAL
Intervention: Self-questionnaire Evaluation Inventory - Parent
Description: Parents must complete the self-questionnaire Evaluation Inventory - Parent after the last session of the Pepps program.

Intervention type: BEHAVIORAL
Intervention: Self-questionnaire Evaluation Inventory - Parent
Description: Parents must complete the self-questionnaire Evaluation Inventory - Parent after the last session of the Pepps program.
Study: NCT06276192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Physiotherapy (diSAID)
Description: The diSAID is developed by the research group and is a modified version of a previously tested exercise program for patients with subacromial pain. The diSAID is distributed in three stages with; Information about subacromial pain, effects of exercise, pain management and ergonomics in everyday living and at work. The training includes exercises for the rotator cuff and scapular stabilizers as well as posterior shoulder stretch. The exercises are performed 1 time/day during twelve weeks with a progression of dose, load and complexity continuously. Pain while performing the exercise program is accepted up until NRS 5 out of 10.~During ongoing treatment, there is the opportunity for counselling, individualization of exercises, adjustment of dose and load based on stated instructions from the treating physiotherapist.~Adherence, levels of pain and function is reported continuously by the patient via the digital platform.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physiotherapy
Description: Patients in the active control group are offered the usual treatment practice that is currently offered by physiotherapists in primary care. No predetermined directives for the active control group are defined prior to the study and can contain; home exercise programs, manual therapy and other techniques. The treating physiotherapists in this group are not involved in the digital treatment. The choice of interventions, amounts of visits and adherence is checked retrospectively via patient data and medical records.
Study: NCT05230238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pituitary gland stimulation
Description: Pituitary gland stimulation via an surface electrode connected to an external neurostimulator
Study: NCT06155968

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QL block
Description: The curvilinear probe (2 5 MHz, SonoSite Turbo M) is placed in the transverse axial plane just cranial to the iliac crest. The shamrock sign was visualised (viz., the transverse process (TP) of vertebra L4 is the stem, whereas the erector spinae muscle (ESM) posteriorly, quadratus lumborum (QL) muscle laterally and the psoas major (PM) muscle anteriorly represent the three leaves). The needle is introduced using an in plane technique from the posterior end of the transducer through the QL muscle. The target for injection is the fascial plane between the QL and PM muscles..

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCA
Description: the PCA pump will be connected in a separate cannula. The pump contains 0.5 mg nalbuphine/ ml. the basal rate is 5ml/h and lock out time is 10 min
Study: NCT05780203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One session exposure treatment
Description: One session exposure treatment during which patients will be confronted with a height-related situation.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: One session exposure treatment
Description: One session exposure treatment during which patients will be confronted with a height-related situation.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Cognitive Bias Modification training
Description: Sham Cognitive Bias Modification training procedure matched in format to active training but adapted to not target height-related, interpretational processing biases.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Cognitive Bias Modification training
Description: Active Cognitive Bias Modification training targeting height-related, interpretational processing biases.
Study: NCT06299696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNZ/TEZ/D-IVA
Description: FDC granules for oral administration
Study: NCT06031701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuro-psychosocial teleassistance program
Description: The intervention is carried out in groups of 5 participants and is organised in 12 sessions: 1 session per week of 1h duration. The intervention is aimed at strengthening aspects of social cognition, self-esteem, social skills and aims at a reduction of symptomatology and a general improvement of psychological well-being.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuro-psychosocial teleassistance program
Description: The intervention is carried out in groups of 5 participants and is organised in 12 sessions: 1 session per week of 1h duration. The intervention is aimed at strengthening aspects of social cognition, self-esteem, social skills and aims at a reduction of symptomatology and a general improvement of psychological well-being.
Study: NCT05997043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral anti-Parkinson drugs and injection of botulinum toxin
Description: The experimental group was treated with oral anti-Parkinson drugs and injection of botulinum toxin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral anti-Parkinson's drugs
Description: The control group only took oral anti-Parkinson's drugs.
Study: NCT06471413

Intervention type: OTHER
Intervention: The Prevention Toolbox : BOAT®
Description: The Prevention Toolbox targets all forms of violence, but in particular sexual and gender-based violence, through 1 out of 5 themes (Relationships and sexuality) and 10 out of 34 sub-themes. The other 4 themes (Psychosocial skills, Respect and difference, From the virtual to the real, and Understanding and respect for the law) cover all the risk and protection factors for all types of violence.
Study: NCT06016179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Each patient will receive four incremental weekly intra-cavitary doses of tocilizumab starting at 0.5μg/mL and increasing to 1.6μg/mL, 5μg/mL and 50μg/mL once a week over four weeks.
Study: NCT04881396

Intervention type: BIOLOGICAL
Intervention: Evaluation of the immunogenicity of the vaccine in haemodialysis patients
Description: The immunogenicity of the vaccine will be evaluated at the peak of vaccine response (Day 7 - Day 14 after the second dose) and 6 and 12 months post vaccination, by the evaluation of humoral IgG anti-spike protein response (seroconversion rate, absolute antibody titers, affinity of antibody) and cellular anti SARS-Cov2 response (number, activation capacity, production of interferon gamma of CD4 and CD8 anti sars cov2 specific T cells)
Study: NCT04520685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral cannabidiol 100mg/mL
Description: In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral cannabidiol 100mg/mL
Description: In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral cannabidiol 100mg/mL
Description: In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
Study: NCT06576453

Intervention type: BEHAVIORAL
Intervention: quiz of knowledge
Description: Parents must complete the quiz of knowledge after the first and the last session of the Pepps program.

Intervention type: BEHAVIORAL
Intervention: quiz of knowledge
Description: Parents must complete the quiz of knowledge after the first and the last session of the Pepps program.

Intervention type: BEHAVIORAL
Intervention: semi-structured interviews (qualitative)
Description: In the month following the last session of the program, the semi-structured interviews (qualitative) will be carried out with parents who have followed either all or part of the sessions of the band.